<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01812551</url>
  </required_header>
  <id_info>
    <org_study_id>02A001</org_study_id>
    <nct_id>NCT01812551</nct_id>
  </id_info>
  <brief_title>Treatment of Low Bone Density in Cystic Fibrosis.</brief_title>
  <acronym>OSCYF</acronym>
  <official_title>Osteoporosis in Cystic Fibrosis: Study of Bone Mass and Bone Metabolism, and Prospective Randomized Therapeutic Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Auxologico Italiano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Telethon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Auxologico Italiano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystic fibrosis (CF) -- an autosomal recessive genetic disease affecting about 60,000
      individuals worldwide, including about 3,800 in Italy -- is often associated with low bone
      mineral mass. The current aggressive therapies have ensured a much longer survival of CF
      patients but this has led to a higher frequency of osteoporosis and bone fractures, a serious
      problem which not only affects quality of life, but also hinders further therapeutic
      measures.

      The aim of this study, conducted on a large group of children, adolescents and young adults
      with CF, has been the evaluation of bone mass changes after 1 year of a simple treatment with
      RDA-adjusted dietary calcium plus 25-OH vitamin D supplementation, and the feasibility and
      efficacy of alendronate treatment (for another year) in patients not responding to calcium +
      25-OH vitamin D alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study included 2 phases.

      Phase 1 (1-year open-label observational study): following baseline evaluation, bone mass
      changes have been studied with a simple therapy of adequate calcium intake and 25-OH vitamin
      D supplements in all eligible subjects (N=171).

      Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study): the 128
      subjects showing an insufficient response to calcium + 25-OH vitamin D alone (bone mass
      increase &lt;5%) at the end of Phase 1, were randomized into 2 groups and assigned to
      alendronate treatment (N=65) or placebo (N=63) (in addition to calcium and 25-OH vitamin D as
      during Phase 1).

      The study has been carried out by the Coordinator's Institution (Istituto Auxologico
      Italiano)in collaboration with most Regional Reference Centers for CF in Italy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone mineral density increase at lumbar spine.</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Bone mineral density evaluated by DXA. Bone mineral apparent density calculated to correct for bone size (growing subjects). Z-score calculated.
Measurements: Phase 1 (171 subjects): Baseline, 6 months, 12 months. Phase 2 (128 subjects, randomized to 2 arms: placebo or alendronate): 18 months, 24 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in bone turnover markers.</measure>
    <time_frame>baseline and up to 24 months</time_frame>
    <description>Bone turnover markers: (serum) osteocalcin (OC), bone specific alkaline phosphatase (BSAP), C-terminal telopeptide of procollagen 1 (CTx); (urine) terminal telopeptide of procollagen 1 (NTx).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fracture rate.</measure>
    <time_frame>at 12th and 24th month</time_frame>
    <description>Appendicular fractures were evaluated at baseline (previous fractures) and throughout the 2 years of study (incident fractures) with X-rays.
Vertebral fractures were evaluated at the end of Phase 1 (12th month) and at the end of Phase 2 (24th month) with lateral thoracic and lumbar spine X-rays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects of alendronate.</measure>
    <time_frame>continuously throughout Phase 2 (2nd year of study)</time_frame>
    <description>Evaluated on the basis of lab tests (calcemia, calciuria, blood cell count, liver and kidney function), FEV1 changes, and other signs/symptoms (e.g. pain, fever, etc.)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Alendronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).
65 subjects were randomized to this arm. Oral alendronate dose: 5 mg/day, if body weight ≤25 kg; 10 mg/day, if body weight &gt;25 kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).
63 subjects were randomized to this arm. Oral placebo (inactive pills).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>As active drug, we used Alendros (Abiogen Pharma, Pisa, Italy), distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).</description>
    <arm_group_label>Alendronate</arm_group_label>
    <other_name>Alendros</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo was distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 2-30 years

          -  clinically stable condition

          -  regular menses in females

          -  low Bone Mineral Apparent Density for age (defined as BMAD Z-score ≤-2.0 if age ≤18
             years or ≤-2.5 if age &gt;18 years).

        Exclusion Criteria:

          -  two or more episodes of hypercalcemia and/or hypercalciuria

          -  contraindications to 25-OH vitamin D or alendronate treatment

          -  recent transplantation

          -  other diseases or medications (glucocorticoids excepted) associated with bone loss.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Luisa Bianchi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Auxologico Italiano</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRR Fibrosi Cistica, Divisione Gastroenterologia, Ospedale Bambin Gesù</name>
      <address>
        <city>Città del Vaticano</city>
        <country>Holy See (Vatican City State)</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRR Fibrosi Cistica, Unità Operativa di Pediatria, Ospedale Misericordia</name>
      <address>
        <city>Grosseto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRR Fibrosi Cistica, Clinica Pediatrica, Policlinico Universitario di Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Auxologico Italiano IRCCS</name>
      <address>
        <city>Milano</city>
        <zip>20145</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Università degli Studi di Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRR Fibrosi Cistica, Dipartimento Pediatria, Università Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRR Fibrosi Cistica Adulti, Azienda Ospedaliera Universitaria San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRR Fibrosi Cistica, Ospedale dei Bambini, ARNAS Civico</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRR Fibrosi Cistica, Dipartimento di Pediatria, Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRR Fibrosi Cistica, Divisione di Pediatria, Istituto Burlo Garofolo</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRR Fibrosi Cistica, Azienda Ospedalierouniversitaria di Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Holy See (Vatican City State)</country>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.lios.it/research/telethon/Bianchi_CF-protocol-2000.pdf</url>
    <description>Study protocol</description>
  </link>
  <link>
    <url>http://www.lios.it/research/telethon/Bianchi_CF-protocol-2000-labtests.pdf</url>
    <description>Lab test information</description>
  </link>
  <reference>
    <citation>Grey AB, Ames RW, Matthews RD, Reid IR. Bone mineral density and body composition in adult patients with cystic fibrosis. Thorax. 1993 Jun;48(6):589-93.</citation>
    <PMID>8346485</PMID>
  </reference>
  <reference>
    <citation>Henderson RC, Madsen CD. Bone density in children and adolescents with cystic fibrosis. J Pediatr. 1996 Jan;128(1):28-34.</citation>
    <PMID>8551418</PMID>
  </reference>
  <reference>
    <citation>Bhudhikanok GS, Lim J, Marcus R, Harkins A, Moss RB, Bachrach LK. Correlates of osteopenia in patients with cystic fibrosis. Pediatrics. 1996 Jan;97(1):103-11.</citation>
    <PMID>8545201</PMID>
  </reference>
  <reference>
    <citation>Baroncelli GI, De Luca F, Magazzú G, Arrigo T, Sferlazzas C, Catena C, Bertelloni S, Saggese G. Bone demineralization in cystic fibrosis: evidence of imbalance between bone formation and degradation. Pediatr Res. 1997 Mar;41(3):397-403.</citation>
    <PMID>9078542</PMID>
  </reference>
  <reference>
    <citation>Humphries IR, Allen JR, Waters DL, Howman-Giles R, Gaskin KJ. Volumetric bone mineral density in children with cystic fibrosis. Appl Radiat Isot. 1998 May-Jun;49(5-6):593-5.</citation>
    <PMID>9569551</PMID>
  </reference>
  <reference>
    <citation>Aris RM, Renner JB, Winders AD, Buell HE, Riggs DB, Lester GE, Ontjes DA. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern Med. 1998 Feb 1;128(3):186-93.</citation>
    <PMID>9454526</PMID>
  </reference>
  <reference>
    <citation>Bhudhikanok GS, Wang MC, Marcus R, Harkins A, Moss RB, Bachrach LK. Bone acquisition and loss in children and adults with cystic fibrosis: a longitudinal study. J Pediatr. 1998 Jul;133(1):18-27.</citation>
    <PMID>9672505</PMID>
  </reference>
  <reference>
    <citation>Henderson RC, Madsen CD. Bone mineral content and body composition in children and young adults with cystic fibrosis. Pediatr Pulmonol. 1999 Feb;27(2):80-4.</citation>
    <PMID>10088930</PMID>
  </reference>
  <reference>
    <citation>Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagni A, Galbiati E, Corona F, Luisetto G, Giuntini D, Picco P, Brandi ML, Falcini F. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum. 2000 Sep;43(9):1960-6.</citation>
    <PMID>11014345</PMID>
  </reference>
  <reference>
    <citation>Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore). 1997 Jul;76(4):266-83. Review.</citation>
    <PMID>9279333</PMID>
  </reference>
  <reference>
    <citation>Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998 Oct 1;339(14):947-52.</citation>
    <PMID>9753709</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2013</study_first_submitted>
  <study_first_submitted_qc>March 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2013</study_first_posted>
  <last_update_submitted>March 5, 2014</last_update_submitted>
  <last_update_submitted_qc>March 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Auxologico Italiano</investigator_affiliation>
    <investigator_full_name>Maria Luisa Bianchi</investigator_full_name>
    <investigator_title>MD, First level manager</investigator_title>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>children</keyword>
  <keyword>adolescents</keyword>
  <keyword>low bone mass</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>alendronate</keyword>
  <keyword>fractures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

